The State Council meeting deployed to deepen the regulatory reform of Pharmaceutical and medical instruments, and Institutions indicated that there are significant structural opportunities in the Pharmaceutical Industry.

According to media reports, the recent State Council executive meeting deployed measures to deepen the regulation reform of pharmaceuticals and medical instruments, promoting the high-quality development of the pharmaceutical industry. Orient stated that looking back at 2024, the high base from the past has been digested, and the intra-hospital rigid demand is being released normally. Meanwhile, the Industry Chain of Innovative Drugs and the export of instruments continue to yield results, and the overall growth logic is clearly visible.

cls.cn19:09 ET

Huawei Shengsi Artificial Intelligence Framework Summit will soon be held to accelerate the prosperity of AI applications

① According to media reports, on December 14, the Shengsi Artificial Intelligence Framework Summit will be held in Beijing. ② CITIC Securities said that the model ecosystem is booming rapidly, and it is expected that in 2025, with the support of upgrading model capabilities and lowering the threshold for industrialization, combined with the implementation of applications such as agents, the commercialization of AI will continue to accelerate.

cls.cnDec 11 19:10 ET

The State-owned Assets Supervision and Administration Commission and the National Development and Reform Commission jointly issued significant venture capital policies, and the equity market is expected to enter a period of development and prosperity.

① The State-owned Assets Supervision and Administration Commission (SASAC) and the National Development and Reform Commission jointly issued policy measures to promote the high-quality development of venture capital funds by central enterprises, supporting these enterprises to initiate and establish venture capital funds, focusing on early-stage, small-scale, long-term investments, and hard technology. ② Citic sec research reports indicate that in the context of the secondary market entering a valuation expansion cycle, with the increasing linkage effect between the primary and secondary markets, the equity market will also move towards a prosperous period of high-quality development.

cls.cnDec 2 19:02 ET

ST Zhizhi was fined for three years of financial fraud. Did the auditing firm Zhitong give a "standard unqualified opinion"? | Quick read announcement.

①Over the years, there has been financial fraud, and special treat Zhizhi has been fined a huge amount, while multiple responsible persons have been banned from the market; ②During the fraud of the company, the annual audit accounting firm has been issuing standard unqualified audit opinions continuously, while the audit fees are also at a relatively high level.

cls.cnNov 26 09:24 ET

The delay in bidding at the hospital end has negatively impacted revenue. Xiangyu Medical is cultivating a second growth curve, with brain-machine products expected to be available for sale as early as this year.

① Due to delays in the bidding activities at the hospital level, Xiangyu Medical experienced a decline in revenue in the first three quarters of 2024. The company is increasing its marketing efforts in areas such as military, exports, home care, private health care, and off-site services; ② Xiangyu Medical's layout in brain-computer interfaces is mainly focused on non-invasive rehabilitation devices, with mental health products expected to be market-ready as early as this year.

cls.cnNov 22 00:59 ET

Subsidiary's slow R&D progress questioned, zhejiang huahai pharmaceutical responds: 'More than 10 products have entered the clinical research stage' | Direct hit on earnings conference

①At the earnings conference, zhejiang huahai pharmaceutical's research and development pipeline progress was questioned by investors. In response, the company's secretary to the board, Zhu Yonghua, provided an overview of the pipeline under development. ②On the zhejiang huahai pharmaceutical side, due to various factors such as the growth of key original research customers, revenue from active pharmaceutical ingredients and formulations business has increased in the first three quarters of this year.

cls.cnNov 20 05:45 ET